glp-1 agonists oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies Frontiers | Glucagon-like peptide-1 receptor

They also slow the movement of food through the digestive system which increases feelings of fullness

A., Kane M

However, to date, extensive RCTs have shown no correlation between specific GLP-1 RAs and increased cancer risk

Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, glucose-dependent insulinotropic polypeptide agonists and other metabolic hormones for the treatment of chronic kidney disease

It is a GLP-1 agonist that can be dangerous when not used appropriately, according to a news release from the manufacturer

In case I do not see you, good afternoon, good evening, and good night.